Lista de obras - Tomáš Štulc - Dominio Público Uruguay

2P-0477 Leukocyte but not endothelial cell adhesion molecules are increased in patients with hypercholesterolemia: The effect of atorvastatin treatment

3P-0795 Apolipoprotein AV polymorphism is the only genetic marker associated with severe hypertriglyceridemia. Results of analysis of four gene loci

article

A comprehensive guidelines-based approach reduces cardiovascular risk in everyday practice: the VARO study

artículo científico publicado en 2016

APOA5 Ala315>Val, identified in patients with severe hypertriglyceridemia, is a common mutation with no major effects on plasma lipid levels

artículo científico publicado en 2008

Age and residual cholesterol efflux affect HDL cholesterol levels and coronary artery disease in ABCA1 heterozygotes.

artículo científico publicado en 2000

Atorvastatin reduces expression of leukocyte adhesion molecules in patients with hypercholesterolemia.

artículo científico publicado en 2003

Effect of folic acid on fenofibrate-induced elevation of homocysteine and cysteine.

artículo científico publicado en 2003

Folate supplementation prevents plasma homocysteine increase after fenofibrate therapy.

artículo científico publicado en 2001

Folic acid does not improve surrogate markers of early atherosclerosis in atorvastatin-treated patients

IMPACT OF APOLIPOPROTEIN A5 GENE VARIANTS ON STATIN TREATMENT EFFICACY

article

Increased levels of pregnancy-associated plasma protein-A in patients with hypercholesterolemia: the effect of atorvastatin treatment.

artículo científico publicado en 2003

Is it safe to combine PPAR agonists? A lesson from muraglitazar

artículo científico publicado en 2006

Ivabradine, coronary heart disease, and heart failure: time for reappraisal.

artículo científico publicado en 2014

PAPP-A, a novel marker of unstable plaque, is not influenced by hypolipidemic treatment in contrast to CRP.

artículo científico publicado en 2003

Prevention of diabetes with rosiglitazone: Evidence of benefit or unexpected harm?

scientific article published on 12 September 2007

ROSIGLITAZONE AND FENOFIBRATE IMPROVE HDL METABOLISM ASSESSED BY FERHDL

Repeatability of noninvasive surrogates of endothelial function

artículo científico publicado en 2004

Statin Intolerance: the Clinician's Perspective

artículo científico publicado en 2015

Statin non-adherence and residual cardiovascular risk: There is need for substantial improvement

artículo científico publicado en 2016

Statins, glycemia, and diabetes mellitus: another point of view

artículo científico

Lista de obras de Tomáš Štulc

2P-0477 Leukocyte but not endothelial cell adhesion molecules are increased in patients with hypercholesterolemia: The effect of atorvastatin treatment

3P-0795 Apolipoprotein AV polymorphism is the only genetic marker associated with severe hypertriglyceridemia. Results of analysis of four gene loci

A comprehensive guidelines-based approach reduces cardiovascular risk in everyday practice: the VARO study

APOA5 Ala315>Val, identified in patients with severe hypertriglyceridemia, is a common mutation with no major effects on plasma lipid levels

Age and residual cholesterol efflux affect HDL cholesterol levels and coronary artery disease in ABCA1 heterozygotes.

Atorvastatin reduces expression of leukocyte adhesion molecules in patients with hypercholesterolemia.

Effect of folic acid on fenofibrate-induced elevation of homocysteine and cysteine.

Folate supplementation prevents plasma homocysteine increase after fenofibrate therapy.

Folic acid does not improve surrogate markers of early atherosclerosis in atorvastatin-treated patients

IMPACT OF APOLIPOPROTEIN A5 GENE VARIANTS ON STATIN TREATMENT EFFICACY

Increased levels of pregnancy-associated plasma protein-A in patients with hypercholesterolemia: the effect of atorvastatin treatment.

Is it safe to combine PPAR agonists? A lesson from muraglitazar

Ivabradine, coronary heart disease, and heart failure: time for reappraisal.

PAPP-A, a novel marker of unstable plaque, is not influenced by hypolipidemic treatment in contrast to CRP.

Prevention of diabetes with rosiglitazone: Evidence of benefit or unexpected harm?

ROSIGLITAZONE AND FENOFIBRATE IMPROVE HDL METABOLISM ASSESSED BY FERHDL

Repeatability of noninvasive surrogates of endothelial function

Statin Intolerance: the Clinician's Perspective

Statin non-adherence and residual cardiovascular risk: There is need for substantial improvement

Statins, glycemia, and diabetes mellitus: another point of view

We-P11:117 Rosiglitazone improves quality of lipoproteins in patients with type 2 diabetes